ReviewSurgery open science2026
Perioperative chemotherapy (FLOT 4 + 4) versus total neoadjuvant therapy (TNT; FLOT ×8) for resectable gastric cancer: A systematic review and exploratory meta-analysis.
Review in Surgery open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric and gastroesophageal junction (GEJ) adenocarcinoma is associated with high recurrence rates despite curative-intent surgery. Standard perioperative chemotherapy (PC) using FLOT (4 preoperative + 4 postoperative cycles) improves survival but is frequently not completed because of postoperative morbidity. Total Neoadjuvant Therapy (TNT), which delivers all eight FLOT cycles preoperatively (FLOT ×8), has been proposed to improve treatment completion. This systematic review and meta-analysis compared TNT with standard perioperative FLOT (FLOT 4 + 4) in resectable gastric cancer. Methods: A systematic search following PRISMA 2020 guidelines was conducted in PubMed, Scopus, EMBASE, ScienceDirect, Cochrane Library, LILACS, and SpringerLink through September 2025. Comparative studies evaluating TNT versus PC in adults with resectable gastric or GEJ adenocarcinoma were included. Primary outcomes were chemotherapy completion and pathological complete response (pCR). Secondary outcomes included R0 resection, postoperative morbidity, treatment-related toxicity, overall survival (OS), and disease-free survival (DFS). Results: Three retrospective comparative studies including 425 patients (136 TNT, 289 PC) were analyzed. TNT was associated with higher completion of planned chemotherapy (OR 4.55; 95% CI 1.13-18.27; p < 0.01) without an increase in major postoperative morbidity (OR 0.96; 95% CI 0.55-1.69; p = 0.50). No significant differences were observed in pCR (OR 1.54; 95% CI 0.65-3.63) or R0 resection rates. Survival outcomes were heterogeneous and could not be reliably pooled. Conclusion: TNT was associated with improved chemotherapy completion without increased perioperative morbidity. However, the current evidence base is insufficient to support conclusions regarding oncologic efficacy or survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.